

Rapid communications

Association of Trp64Arg mutation of the β 3-adrenergic-receptor with NIDDM and body weight gainT. Fujisawa¹, H. Ikegami¹, E. Yamato¹, K. Takekawa¹, Y. Nakagawa¹, Y. Hamada¹, T. Oga¹, H. Ueda¹, M. Shintani¹, M. Fukuda², T. Ogihara¹¹ Department of Geriatric Medicine, Osaka University Medical School, Osaka, Japan² Department of Ophthalmology, Osaka Teishin Hospital, Osaka, Japan

Summary A possible pathogenic mutation in the β 3-adrenergic-receptor gene (Trp64Arg) has been reported to be associated with an earlier age of onset of non-insulin-dependent diabetes mellitus (NIDDM) and clinical features of the insulin resistance syndrome in Pima Indian, Finnish and French subjects. Since marked heterogeneity has been reported in the association of mutations of candidate genes with NIDDM between Japanese and other ethnic groups, we investigated the association of Trp64Arg with NIDDM in Japanese subjects. The allele frequency of the mutation (Arg) was slightly, but not significantly, higher in NIDDM than in control subjects (70 out of 342 alleles [20.5 %] vs 40 out of 248 [16.1 %], respectively, $p > 0.2$). When our data were combined with those of Pima Indian and Finnish subjects, however, the Arg/Arg genotype was significantly associated with NIDDM as compared with the other two genotypes ($p < 0.005$, relative risk

[RR] 2.13, 95 % confidence interval [CI] 1.28–3.55). The Arg allele was also associated with NIDDM ($p < 0.05$, RR 1.27, 95 % CI 1.06–1.52). Japanese subjects homozygous for the mutation had a significantly higher body mass index (mean \pm SD: 25.5 ± 3.9 kg/m²) than heterozygotes (22.6 ± 4.1 , $p < 0.05$) and normal homozygotes (22.8 ± 3.8 , $p < 0.05$). NIDDM patients homozygous for the mutation tended to have an earlier age of onset of NIDDM than those with other genotypes. These data suggest that the Trp64Arg mutation not only contributes to weight gain and age-at-onset of NIDDM but is also associated with susceptibility to NIDDM. [Diabetologia (1996) 39: 349–352]

Keywords β 3-adrenergic-receptor gene, susceptibility, missense mutation, non-insulin-dependent diabetes mellitus, insulin resistance syndrome.

Genetic predisposition is important in the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM) and obesity, but the genes responsible for

the common forms of obesity, insulin resistance and NIDDM are largely unknown. The β 3-adrenergic-receptor (β 3-AR) is predominantly expressed in adipose tissue and plays an important role in lipid metabolism and metabolic rate by mediating lipolysis and thermogenesis, and thus, molecular abnormalities of β 3-AR may lead to obesity and insulin resistance [1]. Recently, three groups [2–4] reported the association of a mutation in the β 3-adrenergic-receptor gene causing a Trp to Arg change at codon 64 (Trp64Arg) with an earlier age of onset of NIDDM [2, 3], clinical features of the insulin resistance syndrome [3] and an increased tendency to gain weight [4].

The marked genetic heterogeneity in the association of NIDDM with mutations in the glycogen syn-

Received: 25 October 1995 and in revised form: 14 December 1995

Corresponding author: Dr. H. Ikegami, Department of Geriatric Medicine, Osaka University Medical School, 2-2 Yamadaoka, Suita, Osaka 565, Japan

Abbreviations: NIDDM, Non-insulin-dependent diabetes mellitus; β 3-AR, β 3-adrenergic-receptor; Trp64Arg, a mutation in the β 3-adrenergic-receptor gene causing a Trp to Arg change at codon 64; BMI, body mass index; ADRB3, β 3-adrenergic receptor gene; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; RR, relative risk; CI, confidence interval.

Table 1. Genotype frequency of the β 3-adrenergic receptor in NIDDM patients and control subjects

| Genotype | Japanese | | Pima Indian ^a | | Finnish ^b | | Total | |
|----------------------------|------------|-----------|--------------------------|------------|----------------------|------------|-------------------------|------------|
| | NIDDM | Control | NIDDM | Control | NIDDM | Control | NIDDM | Control |
| Arg/Arg | 7 (4.1) | 3 (2.4) | 41 (10.5) | 16 (6.3) | 2 (1.0) | 2 (0.7) | 50 (6.5) ^{d,e} | 21 (3.2) |
| Trp/Arg | 56 (32.8) | 34 (27.4) | 173 (44.4) | 117 (46.4) | 36 (17.6) | 68 (23.8) | 265 (34.6) | 219 (33.1) |
| Trp/Trp | 108 (63.1) | 87 (70.2) | 176 (45.1) | 119 (47.3) | 167 (81.4) | 216 (75.5) | 451 (58.9) | 422 (63.7) |
| Relative Risk ^c | | 1.72 | | 1.73 | | 1.40 | | 2.13 |
| 95 % CI | | 0.44–6.71 | | 0.96–3.14 | | 0.2–9.9 | | 1.28–3.55 |

Data are N (%).

^{a,b} Data from references [2] and [3], respectively

^c Relative risks of NIDDM were calculated between subjects

with the Arg/Arg genotype and subjects with the Trp/Arg or Trp/Trp genotype.

^d $p < 0.05$ vs Trp/Arg genotype (RR 1.97, 95 % CI 1.15–3.35);

^e $p < 0.005$ vs Trp/Trp genotype (RR 2.22, 95 % CI 1.33–3.73)

Table 2. Body mass index and age-at-onset of NIDDM in β 3-adrenergic receptor genotypes

| Genotype | Arg/Arg | Trp/Arg | Trp/Trp |
|--|-----------------|-----------------------------|-----------------------------|
| <i>Body mass index, (kg/m²)</i> | | | |
| Japanese | 25.5 \pm 3.9 | 22.6 \pm 4.1 ^d | 22.8 \pm 3.8 ^d |
| Pima ^a | 35.2 \pm 8.0 | 34.1 \pm 7.9 | 33.9 \pm 7.5 |
| Finn, NIDDM ^b | – | 29.1 \pm 4.6 | 27.7 \pm 4.0 |
| French, Obese ^c | – | 51 \pm 9 | 47 \pm 7 |
| <i>Age-at-onset of NIDDM (years)</i> | | | |
| Japanese | 40.4 \pm 19.4 | 43.3 \pm 14.7 | 43.4 \pm 13.3 |
| Pima ^a | 36 \pm 10 | 40 \pm 10 | 41 \pm 11 |
| Finn ^b | – | 56 \pm 11 | 61 \pm 11 |

Data are mean \pm SD.

^a Data from reference [2];

^b Data of western Finland, reference [3];

^c Data from reference [4];

^d $p < 0.05$ vs Arg/Arg genotype

these gene [5] and the glucagon receptor gene [6] between Japanese and other ethnic groups prompted us to investigate the contribution of this mutation with NIDDM and weight gain in a large number of Japanese subjects.

Subjects and methods

Two hundred and ninety-five unrelated Japanese subjects (NIDDM patients: $n = 171$, non-diabetic subjects: $n = 124$) were investigated. NIDDM was diagnosed on the basis of the World Health Organization criteria [7]. Informed consent was obtained from the subjects. Body mass index (BMI) was calculated as weight (in kilograms) divided by height (in meters) squared. Age-at-onset of diabetes was estimated from the time of the first symptoms attributable to the disease and/or the time of first detection of glycosuria.

Genomic DNA was extracted from peripheral blood leukocytes. The Bst NI polymorphism of β 3-adrenergic receptor gene (ADRB3), which detects the Trp64Arg mutation, was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis according to the method of Widén et al. [3].

Statistical analysis

Results are given as mean \pm SD. Differences between group means were tested by the Student's *t*-test. The chi-square test was used to compare frequencies. Relative risk (RR) and 95 % confidence interval (CI) were also calculated.

Results

A Trp64Arg mutation of the β 3-AR was observed in 33.9 % of the subjects, including 10 homozygotes (3.4 %) for the mutation. Overall frequency of the mutated allele in Japanese subjects (18.6 %) was much higher than in Finnish subjects (11.4 %, $p < 1 \times 10^{-4}$) [3], French subjects (4.1 %, $p < 1 \times 10^{-7}$) [4] and Caucasians in the USA (9.1 %, $p < 0.02$) [2], but not Pima Indians (31.5 %, $p < 1 \times 10^{-7}$) [2].

The frequencies of mutated (Arg) allele and Arg/Arg genotype of ADRB3 were slightly, but not significantly, higher in NIDDM than in control subjects (20.5 vs 16.1 %, $p > 0.2$, 4.1 vs 2.4 %, $p > 0.4$, respectively) (Table 1). Since a similar tendency was observed in the Pima Indian and Finnish populations [2, 3] in which the frequencies of the mutation in both NIDDM and control subjects are known, we combined the data of the three population groups (Japanese 295, Pima Indian 642 and Finnish 491). The Arg/Arg genotype was significantly associated with NIDDM as compared with the other two genotypes ($p < 0.005$), with an RR of 2.13 (95 % CI 1.28–3.55). The Arg allele was also significantly associated with NIDDM ($p < 0.05$, RR 1.27, 95 % CI 1.06–1.52) (Table 1).

The BMI (mean \pm SD) of the subjects was 22.8 ± 3.9 kg/m², with a range of 14.4–38.3. Japanese subjects with the Arg/Arg genotype had a significantly higher BMI than those with the Trp/Arg genotype ($p < 0.05$) or the Trp/Trp genotype ($p < 0.05$), as was also observed in Pima Indians [2] and in morbidly obese patients in France [4] (Table 2). Similarly, Japanese NIDDM patients homozygous for the Trp64Arg mutation tended to have an earlier age of onset of NIDDM (Table 2), as was also observed in Pima Indians [2] and Finns [3] (Table 2).

Discussion

Although there were similar tendencies towards a higher frequency of the Arg/Arg genotype of ADRB3 among NIDDM patients in the Japanese, Pima Indian and Finnish populations, this mutated genotype was not significantly associated with NIDDM (Table 1). Analysis of the combined data, however, suggests that the Arg/Arg genotype and the Arg allele were positively associated with NIDDM. The weak association observed within each population may be due to the small numbers of subjects homozygous for the mutation.

With respect to age-at-onset of NIDDM, Japanese patients homozygous for the Trp64Arg mutation tended to have an earlier onset of NIDDM, which was similar to those reported in Pima Indians [2] and Finns [3] (Table 2). Thus, this mutation appears to accelerate the course of NIDDM as well as contribute to its development, and this effect seems to be universal.

The frequency of the mutated allele in the Japanese was higher than those reported in other populations [2–4] except for Pima Indians [2]. The high frequency of the mutated allele in the Japanese whose BMI ($22.8 \pm 3.9 \text{ kg/m}^2$) was lower than those of several other ethnic groups suggests that the mutation itself appears not to be a major determinant of obesity in explaining the racial difference.

Although the Trp64Arg mutation of ADRB3 may not be a major determinant of obesity, it was associated with BMI in Japanese as well as in Pima Indians [2] and in morbidly obese patients in France [4] (Table 2), indicating that it may contribute to weight gain within each population. Taken together, these data suggest that the association of this mutation with weight gain is universal, but the effect is not particularly strong. Given that this mutation predisposes individuals to obesity early in life, it would in turn result in an early onset of NIDDM, but prospective studies in younger subjects are needed to further understand the influence of this mutation on the development of obesity and NIDDM.

The genetic heterogeneity in NIDDM, as suggested by previous studies, emphasizes the importance of genetic studies in NIDDM and other complex traits in different ethnic groups. In contrast to an almost complete lack of the Gly40Ser mutation of the glucagon receptor in Japanese [6] as compared with a 5–8% frequency in French and Sardinians with NIDDM [8], the Trp64Arg mutation of ADRB3 appears to be universally associated with susceptibility to and age-at-onset of NIDDM as well as BMI. Not all the subjects homozygous for Arg/Arg, however, were diabetic, indicating that the mutation itself is not sufficient for the development of NIDDM. These observations suggest that the influence of the Trp64Arg mutation on the development

of NIDDM is not so strong compared with those of other candidate genes, such as the 3243 mutation of mitochondrial DNA in Japanese [9] and Gly40Ser mutation of glucagon receptor gene in French and Sardinians [8]. Thus, the Trp64Arg mutation of ADRB3 appears not to determine, but rather to modify the susceptibility to NIDDM, probably through its effect on metabolic rate and fat accumulation. The calculated relative risk of 2 in Trp64Arg homozygotes for NIDDM seems rather impressive in the light of the complex traits of polygenic disorders such as NIDDM.

Recently, Kadowaki et al. [10] reported similar results; i. e. this mutation is associated with higher BMI in non-diabetic Japanese subjects. In addition, they showed that the mutation was also associated with insulin levels, both fasting and 2-h after glucose load. A lack of detailed information on genotype frequencies in NIDDM patients in their study, however, prevented us from comparing their results with those of our association study with NIDDM.

In conclusion, the high frequency of the Trp64Arg mutation in non-obese Japanese subjects suggests that the mutation itself is not a major determinant of obesity. Within the Japanese population, however, this mutation was associated with higher BMI and earlier age-at-onset of NIDDM, as in other ethnic groups, suggesting that the contribution of this mutation to weight gain and age-at-onset of NIDDM appears to be universal. In addition, combined data analysis suggested that the Trp64Arg mutation is also significantly associated with the development of NIDDM.

Acknowledgements. We thank Ms. Y. Ueno for her skilful technical support. This work was supported in part by a Grant for Diabetes Research from the Ministry of Health and Welfare, a Grant-in-Aid of the Japan Medical Association, a grant from Otsuka Pharmaceutical Co., a grant from the Mochida Memorial Foundation and a grant from the SANDOZ Foundation for Gerontological Research.

References

1. Giacobino JP (1995) β 3-adrenoceptor: an update. *Eur J Endocrinol* 132: 377–385
2. Walston J, Silver K, Bogardus C et al. (1995) Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the β 3-adrenergic-receptor gene. *N Engl J Med* 333: 343–347
3. Widén E, Lehto M, Kanninen T, Walston J, Shuldiner AR, Groop LC (1995) Association of a polymorphism in the β 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. *N Engl J Med* 333: 348–351
4. Clément K, Vaisse C, Manning BSJ et al. (1995) Genetic variation in the β 3-adrenergic-receptor and an increased capacity to gain weight in patients with morbid obesity. *N Engl J Med* 333: 352–354
5. Kadowaki T, Kadowaki H, Yazaki Y (1993) Polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus. *N Engl J Med* 328: 1568–1569

6. Fujisawa T, Ikegami H, Yamato E et al. (1995) A mutation in the glucagon receptor gene (Gly40Ser): heterogeneity in the association with diabetes mellitus. *Diabetologia* 38: 983–985
7. World Health Organization (1985) Diabetes mellitus: report of a WHO Study Group Second report. Geneva, World Health Organization (Tech Rep Ser, no. 727)
8. Hager J, Hansen L, Vaisse C et al. (1995) A missense mutation in the glucagon receptor gene is associated with non-insulin-dependent diabetes mellitus. *Nature Genet* 9: 299–304
9. Kadowaki T, Kadowaki H, Mori Y et al. (1994) A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA. *N Engl J Med* 330: 962–968
10. Kadowaki H, Yasuda K, Iwamoto K et al. (1995) A mutation in the β 3-adrenergic receptor gene is associated with obesity and hyperinsulinemia in Japanese subjects. *Biochem Biophys Res Commun* 215: 555–560